Autolus Therapeutics (AUTL) Deferred Taxes (2020 - 2025)
Autolus Therapeutics' (AUTL) quarterly Deferred Taxes came in at $1.2 million in Q4 2025, up 929.79% YoY from $113615.7 in Q4 2024, and up 9100.0% on a QoQ basis from -$13000.0 in Q3 2025.
Autolus Therapeutics (AUTL) Deferred Taxes (2020 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has 6 years of Deferred Taxes data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Deferred Taxes rose 929.79% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $286000.0 (up 54.59% YoY) and the FY2025 annual result came in at $286000.0, up 54.59% from the prior year.
- Deferred Taxes rose to $1.2 million in Q4 2025, from -$13000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $1.2 million in Q4 2025 to a low of -$487000.0 in Q1 2025.
- A 5-year average of $89850.0 and a median of $164000.0 in 2022 frame the typical range for Deferred Taxes.
- The widest YoY moves for Deferred Taxes: up 929.79% in 2025, down 418.92% in 2025.
- Tracing AUTL's Deferred Taxes over 5 years: stood at $420000.0 in 2021, then tumbled by 175.95% to -$319000.0 in 2022, then surged by 246.08% to $466000.0 in 2023, then plunged by 130.26% to -$141000.0 in 2024, then soared by 929.79% to $1.2 million in 2025.
- The last three Deferred Taxes figures came in at $1.2 million (Q4 2025), -$13000.0 (Q3 2025), and -$384000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.17 Mn |
| Sep 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -384,000.00 |
| Mar 31, 2025 | -487,000.00 |
| Dec 31, 2024 | -141,000.00 |
| Sep 30, 2024 | 168,000.00 |
| Jun 30, 2024 | -74,000.00 |
| Mar 31, 2024 | 232,000.00 |
| Dec 31, 2023 | 466,000.00 |
| Sep 30, 2023 | 238,000.00 |
| Jun 30, 2023 | 87,000.00 |
| Mar 31, 2023 | 195,000.00 |
| Dec 31, 2022 | -319,000.00 |
| Sep 30, 2022 | 160,000.00 |
| Jun 30, 2022 | 253,000.00 |
| Mar 31, 2022 | 174,000.00 |
| Dec 31, 2021 | 420,000.00 |
| Sep 30, 2021 | -233,000.00 |
| Jun 30, 2021 | -395,000.00 |
| Mar 31, 2021 | 280,000.00 |